PrimeGenX Therapeutics Submits Hong Kong IPO Application, Focusing on Differentiated Therapies in Immune-Inflammation Field
According to Hong Kong Exchanges and Clearing disclosure, PrimeGenX Therapeutics Co., Ltd. formally submitted its Main Board listing application on January 21, 2026, with CITIC Securities and CMBC Capital serving as its joint sponsors.
The company positions itself as a biotechnology company focused on the immune-inflammation field, aiming to become a leader in locally delivered targeted therapies. Since its establishment in 2016, the company has leveraged its core capabilities in innovative original design and precise local delivery to deeply explore the chronic inflammatory disease treatment domain.
The prospectus indicates that based on its deep understanding of immune-inflammatory signaling pathways, the company has built an innovative product pipeline with "first-in-class" potential. Its late-stage core product is PG-011 (PuMeiXiTiNi), which has two formulations: PuMeiXiTiNi Gel for atopic dermatitis and PuMeiXiTiNi Nasal Spray for allergic rhinitis. Furthermore, the company's pipeline includes other candidates such as PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma.
The company stated that its R&D philosophy is consistently patient-centric, aiming to provide innovative solutions that combine efficacy, safety, and long-term patient satisfaction to address significant unmet medical needs in the field of chronic inflammatory diseases.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Institution: The supply and demand pattern of the PVC industry is expected to improve, Penghua CSI Subdivision Chemical Industry Theme ETF(159870) rising by 1.66% and aiming for a fourth consecutive day of gains
- End of the three-day rally, Maxwealth CSI Shanghai-Shenzhen-Hong Kong Gold Industry Commodity ETF (517520) falls by more than 3%
- The global AI arms race is providing a core catalyst for the Taiwan market; Ishares Core Msci Taiwan Index Etf (03074.HK) surged more than 1.7% intraday.
- Institution: 2026 is the "turning point year" for the photovoltaic industry, Huatai-PB CSI Photovoltaic Industry ETF(515790) rising by 1.15%
- Institution: Global tech giants are intensifying the implementation of AI applications, Guotai CSI All Share Software ETF (515230) rising nearly 2% in early trading.
